THE WOODLANDS, Texas,
June 15 /PRNewswire-FirstCall/ --
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical
company focused on discovering breakthrough treatments for human
disease, announced today that it will be presenting clinical data
from its Phase 2a clinical trial of LX4211 for patients with type 2
diabetes mellitus at ENDO 2010: The 92nd Annual Meeting and Expo,
June 19 – 22, 2010 in San Diego, California and the 70th Scientific
Sessions of the American Diabetes Association, June 25 – 29,
2010 in Orlando, Florida.
ENDO 2010: The 92nd Annual Meeting and Expo
David Powell, M.D., Lexicon's
senior vice president of metabolism research, will give a
presentation at ENDO 2010 titled "LX4211, a Dual SGLT1 and SGLT2
Inhibitor, Shows Rapid and Significant Improvement in Glycemic
Control over 4 Weeks in Patients with Type 2 Diabetes Mellitus" on
Monday, June 21, 2010 at 11:15 a.m. Pacific Time. Joel Freiman,
M.D., M.P.H., Lexicon's senior medical director will also present a
poster at ENDO 2010 titled "LX4211, a Dual SGLT1 and SGLT2
Inhibitor, Shows Improvements in Cardiovascular Risk Factors over 4
Weeks in Patients with Type 2 Diabetes Mellitus" (poster #P3-511)
on Monday, June 21, 2010 from 1:30 –
3:30 p.m. Pacific Time.
Organized by the Endocrine Society, ENDO 2010 features more than
200 scientific sessions covering the full breadth of endocrinology
— from basic and translational research to clinical practice.
The ENDO 2010 scientific program includes 16 Plenary
lectures, 140 Case Management Forum and Meet-the-Professor sessions
and 78 Symposia — a total of more than 350 presentations from some
of the world's leaders in endocrine research and care. More than
7,500 attendees are expected at this year's conference where 2,500
abstracts will be presented.
70th Scientific Sessions of the American Diabetes
Association
At the 70th Scientific Sessions of the American Diabetes
Association, Dr. Freiman will present a poster titled "LX4211, a
Dual SGLT2/SGLT1 Inhibitor, Shows Rapid and Significant Improvement
in Glycemic Control over 28 Days in Patients with Type 2 Diabetes
(T2DM)" (poster #17-LB) during the poster session titled
"Pharmacologic Treatment of Diabetes or its Complications" on
Monday, June 28, 2010 from 12:00 –
2:00 p.m. Eastern Time.
The 70th Scientific Sessions of the American Diabetes
Association is the largest meeting providing education and
information to all members of the diabetes community, including
physicians, scientists, nurses, nurse practitioners, dietitians,
pharmacists, podiatrists, psychologists and other health care
professionals. More than 15,000 professionals gather each
year to share research, treatment recommendations and advances
toward a cure for diabetes.
About LX4211
LX4211 is an orally-delivered small molecule under development
as a potential treatment for diabetes. LX4211 inhibits both
sodium-glucose cotransporter type 2, or SGLT2, and sodium-glucose
cotransporter type 1, or SGLT1. SGLT2 is a transporter
responsible for most of the glucose reabsorption performed by the
kidney. SGLT1 is a transporter responsible for glucose and
galactose absorption in the gastrointestinal tract, and to a lesser
extent than SGLT2, glucose reabsorption in the kidney. In a
combined Phase 1 single ascending-dose and multiple ascending-dose
study, LX4211 was well tolerated at all dose levels and produced a
dose-dependent increase in urinary glucose excretion. In
preclinical studies, animals treated with LX4211 demonstrated
increased urinary glucose excretion and decreased blood HbA1c
levels (a marker of long-term blood sugar levels).
Importantly, urinary glucose excretion returned to baseline
after treatment was discontinued.
For more information on LX4211, and to access the presentations
(available after June 21 and 28,
2010, respectively), please visit www.lexpharma.com.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
and developing breakthrough treatments for human disease.
Lexicon currently has four drug candidates in mid-stage
development for diabetes, irritable bowel syndrome, carcinoid
syndrome and rheumatoid arthritis, all of which were discovered by
Lexicon's research team. Lexicon has used its proprietary
gene knockout technology to identify more than 100 promising drug
targets. Lexicon has focused drug discovery efforts on these
biologically-validated targets to create its extensive pipeline of
clinical and preclinical programs. For additional information
about Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's clinical development
of LX4211 and the potential therapeutic and commercial potential of
LX4211. This press release also contains forward-looking
statements relating to Lexicon's growth and future operating
results, discovery and development of products, strategic alliances
and intellectual property, as well as other matters that are not
historical facts or information. All forward-looking
statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including those relating to Lexicon's
ability to successfully conduct clinical development of LX4211 and
preclinical and clinical development of its other potential drug
candidates, advance additional candidates into preclinical and
clinical development, obtain necessary regulatory approvals,
achieve its operational objectives, obtain patent protection for
its discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates, that may cause Lexicon's actual results to be
materially different from any future results expressed or implied
by such forward-looking statements. Information identifying
such important factors is contained under "Factors Affecting
Forward-Looking Statements" and "Risk Factors" in Lexicon's annual
report on Form 10-K for the year ended December 31, 2009, as filed with the Securities
and Exchange Commission. Lexicon undertakes no obligation to
update or revise any such forward-looking statements, whether as a
result of new information, future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.